myristic acid has been researched along with Diabetes Mellitus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, BM; Grasso, P; Novakovic, ZM | 1 |
| Ballard, HO; Everson, WV; Gong, M; Graf, GA; Guerin, T; Li, XA; Liu, J; Post, S; Ross, SA; Smart, EJ; Swanson, H; White, J; Zhu, H | 1 |
2 other study(ies) available for myristic acid and Diabetes Mellitus
| Article | Year |
|---|---|
Myristic acid conjugation of [D-Leu-4]-OB3, a biologically active leptin-related synthetic peptide amide, significantly improves its pharmacokinetic profile and efficacy.
Topics: Animals; Diabetes Mellitus; Humans; Leptin; Male; Mice; Mice, Inbred NOD; Mice, Obese; Myristic Acid; Obesity; Peptide Fragments; Peptides; Pharmacokinetics | 2014 |
Diabetic HDL-associated myristic acid inhibits acetylcholine-induced nitric oxide generation by preventing the association of endothelial nitric oxide synthase with calmodulin.
Topics: Acetylcholine; Animals; Calcium; Calmodulin; Cells, Cultured; Diabetes Mellitus; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Endothelial Cells; Estrogens; Female; Humans; Ionomycin; Ionophores; Lipoproteins, HDL; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myristic Acid; Nitric Oxide; Nitric Oxide Synthase Type III; Receptors, Cholinergic; Receptors, Leptin; Signal Transduction | 2008 |